Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenbing decoction III is a Traditional Chinese Medicine (TCM) formulation developed by Southern Medical University Sinowest Medical Hospital (also known as the Southern Medical University Integrated Chinese and Western Medicine Hospital). It is specifically indicated for the treatment of chronic kidney disease (CKD) and the management of renal failure. The formulation is a complex herbal decoction intended to improve renal function and delay the progression of renal failure. It has been evaluated in clinical trials, such as the "Helping Ease Renal Failure with Shenbing Decoction III Trial" (ChiCTR2100049787), to assess its therapeutic efficacy and safety in patients with impaired kidney function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenbing decoction III.